| Drug Type Antibody fusion proteins | 
| Synonyms ES-015.129 | 
| Target | 
| Action stimulants, antagonists | 
| Mechanism IL-2 stimulants(Interleukin-2 stimulants), NKG2A antagonists(killer cell lectin like receptor C1 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | China  | 05 Nov 2024 | 






